The Funding Crisis In Biotech

May 31, 2005 -- Starting a company is hard. There are so many things to worry about, so many new tricks to learn, lots of new groups of people to meet, new ways of thinking to master. Even when the market is easy, it is difficult for the entrepreneur-scientist to figure out how investors think and what they want. When the markets are hard, it can be downright impossible. And they are hard right now. We look at the swing from platform technologies to drugs, the trends in the economy and investing, plus the wretched IPO market to see the current hurdles faced by entrepreneurs wanting to develop a biotech drug...

Back to news